Trial: 201904114

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy
An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma

Phase

II

Principal Investigator

Mehta-Shah, Neha

Disease Site

Mycosis Fungoides; Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov